Buscar
01/03/2026
Gleason pattern 4 and active surveillance in patients with grade group 2 prostate cancer
Uleri, A, Baboudjian, M, Leni, R, Oderda, M, Peyrottes, A, Kesch, C, Al-Nader, M, Dariane, C, Baud, H, Olivier, J, Rios, AR, Sanguedolce, F, Benard, V, Windisch, O, Valerio, M, Gandaglia, G, Ploussard, G. Gleason pattern 4 and active surveillance in patients with grade group 2 prostate cancer. PROSTATE CANCER AND PROSTATIC DISEASES. 2026; 29(1)DOI:10.1038/s41391-025-00977-6. PMID:40301553. IF:5.800(Q1/1D).
01/03/2026
International Delphi consensus on UTUC management: The IMPACT UTUC project
Pandolfo, SD, Contieri, R, Catto, J, Briganti, A, Roupret, M, Pradere, B, Porpiglia, F, Amparore, D, Minervini, A, Bertolo, R, Moschini, M, Mertens, L, Rhijn, BWGV, Gallioli, A, Formisano, L, Imbimbo, C, Lucarelli, G, Ferro, M, Gupta, S, Mir, MC, Derweesh,, Djaladat, H, Bukavina, L, Autorino, R. International Delphi consensus on UTUC management: The IMPACT UTUC project. EUROPEAN UROLOGY. 2026; 89DOI:. PMID:. IF:25.200(Q1/1D).
01/06/2025
The history of Down syndrome-associated Alzheimer's disease; past, present, and future
Maure-Blesa, L, Carmona-Iragui, M, Lott, I, Head, E, Wisniewski, T, Rafii, MS, Espinosa, J, Flórez, J, Mobley, WC, Holland, A, Strydom, A, Zaman, S, Fortea, J. The history of Down syndrome-associated Alzheimer's disease; past, present, and future. ALZHEIMERS & DEMENTIA. 2025; 21(6)DOI:10.1002/alz.70158. PMID:40469048. IF:11.100(Q1/1D).
01/04/2025
Sex differences in clinical phenotypes of behavioral variant frontotemporal dementia
Liu, XL, de Boer, SCM, Cortez, K, Poos, JM, Illán-Gala, I, Heuer, H, Forsberg, LK, Casaletto, K, Memel, M, Appleby, BS, Barmada, S, Bozoki, A, Clark, D, Cobigo, Y, Darby, R, Dickerson, BC, Domoto-Reilly, K, Galasko, DR, Geschwind, DH, Ghoshal, N, Graff-Radford, NR, Grant, IM, Hsiung, GYR, Honig, LS, Huey, ED, Irwin, D, Kantarci, K, Léger, GC, Litvan, I, Mackenzie, IR, Masdeu, JC, Mendez, MF, Onyike, CU, Pascual, B, Pressman, P, Bayram, E, Ramos, EM, Roberson, ED, Rogalski, E, Bouzigues, A, Russell, LL, Foster, PH, Ferry-Bolder, E, Masellis, M, van Swieten, J, Jiskoot, L, Seelaar, H, Sanchez-Valle, R, Laforce, R, Graff, C, Galimberti, D, Vandenberghe, R, de Mendonça, A, Tiraboschi, P, Santana, I, Gerhard, A, Levin, J, Sorbi, S, Otto, M, Pasquier, F, Ducharme, S, Butler, CR, Le Ber, I, Finger, E, Rowe, JB, Synofzik, M, Moreno, F, Borroni, B, Boeve, BF, Boxer, AL, Rosen, HJ, Pijnenburg, YAL, Rohrer, JD, Tartaglia, MC. Sex differences in clinical phenotypes of behavioral variant frontotemporal dementia. ALZHEIMERS & DEMENTIA. 2025; 21(4)DOI:10.1002/alz.14608. PMID:40277074. IF:11.100(Q1/1D).
01/10/2024
Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF-AD study
Smith, RG, Pishva, E, Kouhsar, M, Imm, J, Dobricic, V, Johannsen, P, Wittig, M, Franke, A, Vandenberghe, R, Schaeverbeke, J, Freund-Levi, Y, Frölich, L, Scheltens, P, Teunissen, CE, Frisoni, G, Blin, O, Richardson, JC, Bordet, R, Engelborghs, S, de Roeck, E, Martinez-Lage, P, Altuna, M, Tainta, M, Lleó, A, Sala, I, Popp, J, Peyratout, G, Winchester, L, Nevado-Holgado, A, Verhey, F, Tsolaki, M, Andreasson, U, Blennow, K, Zetterberg, H, Streffer, J, Vos, SJB, Lovestone, S, Visser, PJ, Bertram, L, Lunnon, K. Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF-AD study. ALZHEIMERS & DEMENTIA. 2024; 20(10)DOI:10.1002/alz.14098. PMID:39193893. IF:11.100(Q1/1D).
01/04/2026
First-in-class SAM-competitive G9a inhibitor FLAV-27 as adisease-modifying therapy for Alzheimer disease
Bellver-Sanchis, A, Valle-Garcia, D, Barbaraci, C, Romero-Becerra, F, Singh, RK, Jarne-Ferrer, J, Vasilopoulou, F, Irisarri, A, Martínez-Fernández, C, Fafián-Labora, JA, Arufe, MC, Wüst, C, Castellanos, A, Soto, D, Casals, N, Fadó, R, Pocock, JM, Navarro, G, Val, C, Brea, J, Loza, MI, Lleó, A, Fortea, J, Alcolea, D, Perez-Bosque, A, Miró, L, Pérez, B, Rashid, S, Ali, M, Saqib, M, li Carbó, M, Guerrero, A, Vázquez, S, Choudhary, BS, Dai, SD, Escolano, C, Franco, R, Pallàs, M, Griñán-Ferré, C. First-in-class SAM-competitive G9a inhibitor FLAV-27 as adisease-modifying therapy for Alzheimer disease. MOLECULAR THERAPY. 2026; 34(4)DOI:10.1016/j.ymthe.2025.12.038. PMID:41445192. IF:12.000(Q1/1D).